TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28870554
Drug: Conventional professional
Normalized name: Clearskin Professional Daily Correcting
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional professional based speech language therapy (SLT) assisted by computer based language therapy software (Group B/more intensive)
Study: 23416804
Drug: Peppermint oil,
Normalized name: Peppermint Oil, NF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint oil, administered three times daily for six weeks
Study: 23416804
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered three times daily for six weeks
Study: 15673985
Drug: St. John's
Normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St. John's wort extract (SJW) 600 mg (standardized to contain 1800 microg of hypericin)
Study: 11408053
Drug: Dual-task performance
Normalized name: Perform
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-task performance in depressed patients prior to antidepressant treatment
Study: 9203932
Drug: Loxiglumide (CCK‐A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxiglumide (CCK‐A receptor antagonist) at 10 mg/kg/h
Study: 9203932
Drug: Paired saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired saline infusion
Study: 7869908
Drug: Delta TSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta TSA exceeding 10 mg/dL
Study: 7869908
Drug: Delta TSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta TSA not exceeding 10 mg/dL
Study: 2081793
Drug: Oral immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immune globulin preparation
Study: 367576
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine, methyl‐CCNU, and methotrexate with MER‐BCG
Study: 367576
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine, methyl‐CCNU, and methotrexate without MER‐BCG
Study: 367576
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of vincristine, methyl‐CCNU, and methotrexate (with or without MER‐BCG)
Study: 31657981
Drug: Additional intrathecal
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional intrathecal therapy (two extra doses)
Study: 31657981
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional intrathecal therapy
Study: 25406858
Drug: Usual homecare
Normalized name: Welmedix Homecare Pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual homecare re‐ablement plus an enhanced program targeted at activities of daily living (ADL), delivered by an occupational therapist.
Study: 25406858
Drug: Usual homecare
Normalized name: Welmedix Homecare Pro
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual homecare re‐ablement (without routine occupational therapy input).
Study: 22785005
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy (O(2))
Study: 21352267
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER 8 mg
Study: 12153960
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 micro g once daily (n = 13)
Study: 10089948
Drug: Oral fluoropyrimidines
Normalized name: 5-Fluoropyrimidine-2,4-dione
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral fluoropyrimidines (o-FPs)
Study: 30207807
Drug: HP 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 0.01% lotion
Study: 30207807
Drug: HP 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP 0.05% cream
Study: 25877021
Drug: 10-mg intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg intramuscular metoclopramide prior to operation
Study: 15219269
Drug: Budesonide/formoterol adjustable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol adjustable maintenance dosing (two inhalations bid; stepping up to four inhalations bid if asthma worsened for a maximum of 14 days; stepping down to two inhalations once nocte or one inhalation bid if symptoms were controlled)
Study: 15219269
Drug: Budesonide/formoterol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol fixed maintenance dosing (two inhalations bid)
Study: 11690735
Drug: Gabapentin 1800
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin 1800 mg/day and 2400 mg/day
Study: 1546861
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA, 10 to 15 mg/kg body weight per day) for 6 weeks
Study: 25911824
Drug: Domperidone suspension
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone suspension (0.3 mg x kg(-1) x d(-1), tid, orally 30 minutes before meals)
Study: 17917611
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg oral capsules three times daily for 4 weeks
Study: 17917611
Drug: Gabapentin 300
Normalized name: gabapentin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 300 mg oral capsules
Study: 12839718
Drug: Modified Danger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Danger Ideation Reduction Therapy (DIRT)
Study: 29959110
Drug: Qualitative-only analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative-only analysis for drug question (n=58)
Study: 29959110
Drug: NLP analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP analysis for drug question
Study: 29959110
Drug: Qualitative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative and NLP-augmented analysis for drug question
Study: 29959110
Drug: NLP-only approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP-only approach for drug question
Study: 29959110
Drug: Qualitative-only approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative-only approach for drug question
Study: 29959110
Drug: Qualitative analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualitative analysis followed by qualitative- or NLP-augmented analysis for drug question
Study: 29959110
Drug: NLP analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: NLP analysis followed by qualitative analysis for drug question
Study: 24141698
Drug: palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 0.25 or 0.75 mg
Study: 24141698
Drug: palonosetron 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 0.75 mg
Study: 22711895
Drug: Intranasal ROX-828
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ROX-828 (31.5 mg ketorolac tromethamine/200 µL, containing 6% of lidocaine)
Study: 22711895
Drug: Intranasal ROX-828
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ROX-828
Study: 19226292
Drug: MgSO(4)/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: MgSO(4)/L
Study: 12908666
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment added to existing treatment options
Study: 12908666
Drug: Existing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Existing treatment options
Study: 10821991
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral carvedilol
Study: 17033273
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg carvedilol
Study: 3899771
Drug: Sustained-release clomipramine
Normalized name: clomipramine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release clomipramine (Anafranil SR) 75 mg once daily
Study: 3899771
Drug: Conventional formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional formulation of clomipramine (Anafranil) 75 mg once daily
Study: 24820768
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (MgO) with H2 receptor antagonist (H2RA)
Study: 24820768
Drug: Magnesium oxide
Normalized name: Magnesium Oxide
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium oxide (MgO) with proton pump inhibitor (PPI)
Study: 15975759
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (IPEC) consisting of doxorubicin, 0.1mg/kg and cisplatin, 15 mg/m² per day for 5 consecutive days.
Study: 10469101
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of pulsed CO2 laser followed by Q-switched alexandrite laser
Study: 7563337
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 sterile solution
Study: 7563337
Drug: Pediatric sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric sterile solution (placebo)
Study: 22985205
Drug: CBT +
Normalized name: Cannabidiol
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CBT + fluoxetine
Study: 23375165
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A (types 1:2:3 = 3:100:100 DU)
Study: 23375165
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B (types 1:2:3 = 1.5:50:50 DU)
Study: 23375165
Drug: Vaccine C
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine C (types 1:2:3 = 0.75:25:25 DU)
Study: 21441782
Drug: PHiD‐CV (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV (3 doses)
Study: 21441782
Drug: PHiD‐CV (2-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD‐CV (2-dose catch-up)
Study: 19944004
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with no-updosing regimen
Study: 19944004
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) with traditional updosing approach
Study: 16816491
Drug: C. pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. pen and gentamicin intravenously (IV), followed by oral amoxicillin
Study: 16816491
Drug: amox-clav IV,
Approvals — FDA: no, EMA: no, PMDA: no
Description: amox-clav IV, followed by oral amox-clav
Study: 14594793
Drug: Intraperitoneal amino
Normalized name: silk amino acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal amino acid solution (2 L, 1.1%)
Study: 14594793
Drug: Intraperitoneal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal glucose solution (2.27%)
Study: 10659979
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate (900 mg/day)
Study: 8362600
Drug: s.c. rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. rIL-2 at doses of 4.8-14.4 million IU/m2/day on 5 days per week
Study: 8362600
Drug: s.c. rIL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: s.c. rIL-2 in combination with s.c. rIFN-alpha at 14.4-18.0 million IU/m2/day on days 1 and 2, followed by 4.8 million IU/m2/day, 5 days per week
Study: 2433307
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin (IVGG) plus aspirin (ASA)
Study: 20395260
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) Q5 (>5.1-6.9 mmol/L)
Study: 20395260
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma glucose (FPG) Q5e (5.8-6.9 mmol/L)
Study: 18962988
Drug: Escitalopram 10
Normalized name: escitalopram 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram 10 mg/day for 6 weeks
Study: 15478314
Drug: Oral E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral E2 valerate 2-4 mg/day
Study: 15478314
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 50-100 microg/day
Study: 11487675
Drug: Alteplase (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alteplase (2 mg per 2 mL)
Study: 9777425
Drug: Intramuscular cyanocobalamin
Normalized name: Cyanocobalamin
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular cyanocobalamin injections
Study: 8797622
Drug: Rectal temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal temperature
Study: 3046651
Drug: Pre-operative prophylactic
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative prophylactic dose of a combination of crystalline penicillin and chloramphenicol
Study: 30341773
Drug: 10% CPP-ACP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% CPP-ACP crème applied three times daily
Study: 27849566
Drug: Sacubitril/valsartan 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan 400 mg once daily for 4 weeks
Study: 27849566
Drug: Valsartan 320
Normalized name: valsartan 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 320 mg once daily for 4 weeks
Study: 26306691
Drug: Patient-centered systematic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centered systematic drug review intervention by trained primary care physicians (PCPs)
Study: 21227601
Drug: Days of
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days of use during treatment
Study: 16480471
Drug: 2-chloroprocaine 30
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-chloroprocaine 30 mg/ml
Study: 16480471
Drug: Lidocaine 20
Normalized name: lidocaine 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 20 mg/ml with 5 microg/ml epinephrine
Study: 12900689
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg x kg‐1 of caffeine in the AM and 2.5 mg x kg‐1 of caffeine in the PM (trial A)
Study: 12900689
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg x kg‐1 of caffeine in the AM and placebo in the PM (trial C)
Study: 12900689
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the AM and 5 mg x kg‐1 of caffeine in the PM (trial D)
Study: 11180196
Drug: Uroxin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uroxin (400 mg)
Study: 11180196
Drug: Noroxin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noroxin (400 mg)
Study: 9420044
Drug: Intravenous itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous itraconazole (200 mg) administered as four 1-hour infusions on days 1-2, followed by daily 1-hour infusions of 200 mg from days 3-7.
Study: 9420044
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution (200 mg once daily) after i.v. treatment.
Study: 9420044
Drug: Oral itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole solution (200 mg twice daily) after i.v. treatment.
Study: 9420044
Drug: Intravenous treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment phase compared to oral treatment phase.
Study: 8237748
Drug: Theophylline (aminophylline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (aminophylline, mean concentration 16.1 mg/L)
Study: 29033381
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg intravenous infusion once yearly for 2 years
Study: 22621776
Drug: Intranasal BDP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal BDP HFA 80 μg
Study: 22621776
Drug: Intranasal BDP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal BDP HFA 320 μg
Study: 22621776
Drug: Orally inhaled
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally inhaled BDP HFA 320 μg
Study: 22621776
Drug: Intranasal BDP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal BDP HFA 320 μg vs Orally inhaled BDP HFA 320 μg
Study: 22621776
Drug: Intranasal BDP
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal BDP HFA 80 μg vs 320 μg
Study: 19880495
Drug: EBV-specific cytotoxic
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBV-specific cytotoxic T lymphocytes (CTLs) treatment
Study: 17655686
Drug: EZE/SIMVA 10/10-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZE/SIMVA 10/10-, 10/20-, 10/40-, or 10/80-mg
Study: 17655686
Drug: SIMVA 10-,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIMVA 10-, 20-, 40-, or 80-mg
Study: 12235450
Drug: Atovaquone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atovaquone (250 mg daily) plus chloroguanide (100 mg daily)
Study: 2686421
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg IV every 12 hours followed by 500 mg orally every 12 hours)
Study: 2686421
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g IV every 8 to 12 hours)
Study: 26311325
Drug: SMS reminders
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS reminders for each dose of medicine in addition to the standard of care.
Study: 21546500
Drug: Histamine dihydrochloride
Normalized name: Histamine dihydrochloride
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Histamine dihydrochloride plus low-dose interleukin-2
Study: 16950752
Drug: rhGH (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (0.4 mg/day for males, 0.6 mg/day for females) for 12 months
Study: 16841668
Drug: Jinghua Weikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinghua Weikang Capsule (JWC) high-dose 160 mg, 3 times per day for 14 days
Study: 16841668
Drug: Jinghua Weikang
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jinghua Weikang Capsule (JWC) low-dose 80 mg, 3 times per day for 14 days
Study: 16841668
Drug: Domperidone 10
Normalized name: domperidone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone 10 mg, 3 times per day for 14 days (Control group)
Study: 1836918
Drug: 2 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 micrograms intradermal injection
Study: 1836918
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms intramuscular injection
Study: 6120717
Drug: Lormetazepam (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lormetazepam (0.5, 1.0, and 2.0 mg)
Study: 6120717
Drug: Camazepam (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camazepam (10-20 mg)
Study: 15068402
Drug: Methylphenidate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (1 mg/kg/day)
Study: 15000770
Drug: Innovo insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Innovo insulin doser
Study: 7972311
Drug: Control (diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (diltiazem 120 mg orally without grapefruit juice)
Study: 2657428
Drug: Prednisone, 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 0.75 mg/kg/day (n = 33)
Study: 2657428
Drug: Prednisone, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 1.5 mg/kg/day (n = 34)
Study: 2657428
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone (1.5 mg/kg/day)
Study: 30726692
Drug: Omadacycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omadacycline (100 mg intravenously every 12 hours for two doses, then 100 mg intravenously every 24 hours; transition to oral 300 mg every 24 hours after 3 days)
Study: 30726692
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg intravenously every 24 hours; transition to oral 400 mg every 24 hours after 3 days)
Study: 26482031
Drug: Negative-pressure incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative-pressure incision therapy device applied for 5-7 days
Study: 22429618
Drug: Topical mydriatics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical mydriatics (TM) - cyclopentolate 0.85%, phenylephrine 1.5%, xylocaine 1% intracamerally
Study: 17389556
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper back
Study: 17389556
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to chest
Study: 17389556
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to abdomen
Study: 17389556
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to thigh
Study: 17389556
Drug: Rivastigmine transdermal
Normalized name: Rivastigmine Transdermal System
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine transdermal patch (10-cm², 18 mg) applied to upper arm
Study: 11875330
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with 2 mg estradiol valerate and 1 mg cyproterone acetate (n = 15)